JP5442906B2 - キナーゼインヒビターおよびこれを用いた癌の治療方法 - Google Patents

キナーゼインヒビターおよびこれを用いた癌の治療方法 Download PDF

Info

Publication number
JP5442906B2
JP5442906B2 JP2013502966A JP2013502966A JP5442906B2 JP 5442906 B2 JP5442906 B2 JP 5442906B2 JP 2013502966 A JP2013502966 A JP 2013502966A JP 2013502966 A JP2013502966 A JP 2013502966A JP 5442906 B2 JP5442906 B2 JP 5442906B2
Authority
JP
Japan
Prior art keywords
mmol
cancer
indazol
title compound
indoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013502966A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523784A5 (enExample
JP2013523784A (ja
Inventor
ブレント サンプソン，ピーター
リウ，ヨン
リー，セー−ワン
ティー． フォレスト，ブライアン
ダブリュ． ポールズ，ハインズ
ジー． エドワーズ，ルイーズ
フェーヘル，ミクロス
クマール ビー． パテル，ナレンドラ
ラウファー，ラドスロー
パン，クオホア．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Original Assignee
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CA2010/000518 external-priority patent/WO2010115279A1/en
Application filed by University Health Network filed Critical University Health Network
Publication of JP2013523784A publication Critical patent/JP2013523784A/ja
Publication of JP2013523784A5 publication Critical patent/JP2013523784A5/ja
Application granted granted Critical
Publication of JP5442906B2 publication Critical patent/JP5442906B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
JP2013502966A 2010-04-06 2011-04-06 キナーゼインヒビターおよびこれを用いた癌の治療方法 Active JP5442906B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US32132910P 2010-04-06 2010-04-06
US32133210P 2010-04-06 2010-04-06
PCT/CA2010/000518 WO2010115279A1 (en) 2009-04-06 2010-04-06 Kinase inhibitors and method of treating cancer with same
US61/321,332 2010-04-06
CAPCT/CA2010/000518 2010-04-06
US61/321,329 2010-04-06
PCT/CA2011/000386 WO2011123946A1 (en) 2010-04-06 2011-04-06 Kinase inhibitors and method of treating cancer with same

Publications (3)

Publication Number Publication Date
JP2013523784A JP2013523784A (ja) 2013-06-17
JP2013523784A5 JP2013523784A5 (enExample) 2013-07-25
JP5442906B2 true JP5442906B2 (ja) 2014-03-19

Family

ID=44761967

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013502966A Active JP5442906B2 (ja) 2010-04-06 2011-04-06 キナーゼインヒビターおよびこれを用いた癌の治療方法

Country Status (25)

Country Link
US (9) US8921545B2 (enExample)
EP (2) EP2556071B1 (enExample)
JP (1) JP5442906B2 (enExample)
KR (1) KR101782668B1 (enExample)
CN (1) CN102892766B (enExample)
AU (1) AU2011238384B2 (enExample)
BR (1) BR112012025496B1 (enExample)
CY (1) CY1118610T1 (enExample)
DK (1) DK2556071T3 (enExample)
EA (1) EA023173B1 (enExample)
ES (2) ES2603613T3 (enExample)
HR (1) HRP20161498T1 (enExample)
HU (1) HUE030651T2 (enExample)
IL (1) IL221556A (enExample)
LT (1) LT2556071T (enExample)
ME (1) ME02545B (enExample)
MX (1) MX2012011516A (enExample)
NZ (1) NZ602350A (enExample)
PL (1) PL2556071T3 (enExample)
PT (1) PT2556071T (enExample)
SG (1) SG183875A1 (enExample)
SI (1) SI2556071T1 (enExample)
SM (1) SMT201600430B (enExample)
TW (1) TWI516262B (enExample)
WO (2) WO2011123946A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009079767A1 (en) 2007-12-21 2009-07-02 University Health Network Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer
CA2756568C (en) 2009-04-06 2018-02-13 University Health Network Kinase inhibitors and method of treating cancer with same
ES2603613T3 (es) 2010-04-06 2017-02-28 University Health Network Inhibidores de quinasa y su uso en el tratamiento del cáncer
CA2803446C (en) * 2010-07-02 2019-06-04 University Health Network Use of plk4 antagonists for treating pten mutant diseases
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
JP5965484B2 (ja) * 2012-07-27 2016-08-03 佐藤製薬株式会社 ジフルオロメチレン化合物
KR20220063299A (ko) * 2013-10-18 2022-05-17 유니버시티 헬스 네트워크 Plk-4 억제제의 염 및 결정체들
WO2015054781A1 (en) * 2013-10-18 2015-04-23 University Health Network Treatment for pancreatic cancer
CN104130175A (zh) * 2014-06-13 2014-11-05 天津科技大学 不同位置取代吲哚酮类衍生物及其应用
CN110072865B (zh) 2017-02-08 2022-02-11 中国医药研究开发中心有限公司 吡咯并芳杂环类化合物及其制备方法和医药用途
CN108947970B (zh) * 2017-05-18 2022-04-05 四川大学 吲唑类衍生物及其制备方法和用途
JP7343483B2 (ja) * 2017-09-08 2023-09-12 ユニバーシティー ヘルス ネットワーク Ｐｏｌｏ様キナーゼ４の阻害のための併用療法
WO2020097400A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
US12522583B2 (en) 2018-11-07 2026-01-13 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
WO2020097398A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
JP7705351B2 (ja) 2019-04-24 2025-07-09 ユニバーシティー ヘルス ネットワーク ＰＬＫ４阻害剤である（１Ｒ，２Ｓ）－（Ｅ）－２－（３－（４－（（ｃｉｓ－２，６－ジメチルモルホリノ）メチル）スチリル）－１Ｈ－イミダゾール－６－イル）－５’－メトキシスピロ［シクロプロパン－１，３’－インドリン］－２’－オンフマル酸塩のＳ４結晶形
TWI880995B (zh) * 2019-12-06 2025-04-21 加拿大健康網路大學 急性骨髓性白血病或骨髓發育不良症候群的治療
TW202204350A (zh) 2020-05-06 2022-02-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
CN112250614B (zh) * 2020-10-20 2022-02-01 苏州大学 3-螺三元环吲哚酮衍生物的合成方法
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
TW202300485A (zh) * 2021-03-02 2023-01-01 大陸商上海齊魯製藥研究中心有限公司 Plk4抑制劑及其用途
CN117794529B (zh) 2021-05-11 2025-02-11 欧瑞克制药公司 Polo样激酶4抑制剂
CN115677682B (zh) * 2021-07-30 2023-07-18 上海齐鲁制药研究中心有限公司 螺环类plk4抑制剂及其用途
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2
US20260015351A1 (en) * 2022-06-30 2026-01-15 Axonis Therapeutics, Inc. Methods and compounds for inhibiting mkk7 enzymes
CR20250419A (es) 2023-04-06 2025-10-07 Pfizer Compuestos de derivados de ácido indazol propiónico sustituidos y usos de estos

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3310891A1 (de) 1983-03-25 1984-09-27 Boehringer Mannheim Gmbh, 6800 Mannheim Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
US5182397A (en) * 1990-05-31 1993-01-26 American Cyanamid Company Aryloxyspiroalkylindolinone herbicides
GB9507298D0 (en) 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
EP1247803A3 (en) 1996-08-23 2002-10-16 Sugen, Inc. Indolinone compounds suitable for modulation of protein kinases
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
WO2000008202A2 (en) 1998-08-04 2000-02-17 Sugen, Inc. 3-methylidenyl-2-indolinone modulators of protein kinase
EP1165513A1 (en) 1999-03-24 2002-01-02 Sugen, Inc. Indolinone compounds as kinase inhibitors
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
CA2410509A1 (en) 2000-06-02 2001-12-13 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
TW200406385A (en) 2002-05-31 2004-05-01 Eisai Co Ltd Pyrazole compound and pharmaceutical composition containing the same
US7148249B2 (en) * 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
AU2003286604A1 (en) 2002-10-21 2004-05-13 Irm Llc Oxindoles with anti-hiv activity
EP1696906A1 (en) 2003-12-16 2006-09-06 Leo Pharma A/S Novel therapeutic use of indolinone derivatives
US20050211590A1 (en) 2004-03-26 2005-09-29 Mcclure George K Protective cover for medical devices
DE102005005395A1 (de) 2005-02-03 2006-08-10 Schering Aktiengesellschaft Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
US7309787B2 (en) 2005-07-13 2007-12-18 Allergan, Inc. Kinase inhibitors
WO2007058626A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
US20070135509A1 (en) 2005-12-09 2007-06-14 Blackburn Thomas P Indolone compounds useful to treat cognitive impairment
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
WO2007109026A2 (en) 2006-03-15 2007-09-27 The Trustees Of Columbia University In The City Of New York Pten compositions and methods for detecting breast cancer
GB0606234D0 (en) 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
CA2690567A1 (en) * 2007-06-12 2008-12-18 Boehringer Ingelheim International Gmbh 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases
NZ584760A (en) 2007-09-25 2012-03-30 Takeda Pharmaceutical Polo-like kinase inhibitors
CA2706075A1 (en) 2007-11-20 2009-05-28 University Health Network Cancer diagnostic and therapeutic methods that target plk4/sak
JP2009173629A (ja) * 2007-12-21 2009-08-06 Banyu Pharmaceut Co Ltd Ｒｓｋ１阻害作用を有する新規スピロインダン誘導体
WO2009079767A1 (en) 2007-12-21 2009-07-02 University Health Network Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer
EP2262499B1 (en) * 2008-03-11 2016-12-21 University Health Network Mk-0557 for use in the treatment of cancer
EP2108641A1 (en) * 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) * 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
AU2009271406A1 (en) 2008-06-16 2010-01-21 Tigris Pharmaceuticals, Inc. Methods for determining sensitivity to aminoflavones
DE102008040187A1 (de) * 2008-07-04 2010-01-07 Robert Bosch Gmbh Sensorelement, Verfahren zu seiner Herstellung sowie Verwendung
US8455477B2 (en) 2008-08-05 2013-06-04 Merck Sharp & Dohme Corp. Therapeutic compounds
CA2756568C (en) 2009-04-06 2018-02-13 University Health Network Kinase inhibitors and method of treating cancer with same
WO2011069298A1 (en) 2009-12-11 2011-06-16 F. Hoffmann-La Roche Ag Novel cyclopropane indolinone derivatives
JP5056876B2 (ja) 2010-03-19 2012-10-24 Ｊｆｅスチール株式会社 冷間加工性と焼入れ性に優れた熱延鋼板およびその製造方法
ES2603613T3 (es) 2010-04-06 2017-02-28 University Health Network Inhibidores de quinasa y su uso en el tratamiento del cáncer
CA2803446C (en) * 2010-07-02 2019-06-04 University Health Network Use of plk4 antagonists for treating pten mutant diseases
WO2012048411A1 (en) 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
EP2643314B1 (en) 2010-11-25 2016-07-13 ratiopharm GmbH Novel salts and polymorphic forms of afatinib
EP2681216B1 (en) 2011-02-28 2017-09-27 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
GB201109966D0 (en) 2011-06-10 2011-07-27 Cancer Res Inst Royal Materials and methods for treating pten mutated or deficient cancer
EP2766352B1 (en) 2011-10-12 2018-06-06 University Health Network (UHN) Indazole compounds as kinase inhibitors and method of treating cancer with same
KR20220063299A (ko) 2013-10-18 2022-05-17 유니버시티 헬스 네트워크 Plk-4 억제제의 염 및 결정체들
WO2015054781A1 (en) 2013-10-18 2015-04-23 University Health Network Treatment for pancreatic cancer

Also Published As

Publication number Publication date
US8481533B2 (en) 2013-07-09
WO2011123946A1 (en) 2011-10-13
EP2556070A4 (en) 2013-10-23
BR112012025496A2 (pt) 2020-08-18
US20170226088A1 (en) 2017-08-10
CN102892766B (zh) 2015-05-20
LT2556071T (lt) 2017-01-25
EP2556071A4 (en) 2013-09-04
AU2011238384A1 (en) 2012-09-27
EA023173B1 (ru) 2016-04-29
US20150133677A1 (en) 2015-05-14
EP2556071B1 (en) 2016-08-17
TW201134471A (en) 2011-10-16
ES2639757T3 (es) 2017-10-30
JP2013523784A (ja) 2013-06-17
KR20130108065A (ko) 2013-10-02
US20140045838A1 (en) 2014-02-13
PL2556071T3 (pl) 2017-02-28
EP2556070B1 (en) 2017-06-07
DK2556071T3 (en) 2016-12-12
SI2556071T1 (sl) 2016-12-30
US20180105511A1 (en) 2018-04-19
US20180282306A1 (en) 2018-10-04
WO2011123947A1 (en) 2011-10-13
ME02545B (me) 2017-02-20
WO2011123946A8 (en) 2011-12-08
NZ602350A (en) 2014-05-30
US9139563B2 (en) 2015-09-22
US20120264800A1 (en) 2012-10-18
US20110263598A1 (en) 2011-10-27
US20160045511A1 (en) 2016-02-18
US10358436B2 (en) 2019-07-23
ES2603613T3 (es) 2017-02-28
MX2012011516A (es) 2013-03-08
TWI516262B (zh) 2016-01-11
EP2556071A1 (en) 2013-02-13
US8263596B2 (en) 2012-09-11
IL221556A (en) 2015-04-30
US8921545B2 (en) 2014-12-30
EA201270752A1 (ru) 2013-04-30
US20130096301A1 (en) 2013-04-18
US9907800B2 (en) 2018-03-06
PT2556071T (pt) 2016-11-22
SG183875A1 (en) 2012-10-30
CY1118610T1 (el) 2017-07-12
US9796703B2 (en) 2017-10-24
HUE030651T2 (en) 2017-05-29
WO2011123947A8 (en) 2011-12-22
BR112012025496B1 (pt) 2021-02-23
US10077255B2 (en) 2018-09-18
SMT201600430B (it) 2017-01-10
EP2556070A1 (en) 2013-02-13
AU2011238384B2 (en) 2015-02-19
CN102892766A (zh) 2013-01-23
HRP20161498T1 (hr) 2016-12-16
US9579327B2 (en) 2017-02-28
KR101782668B1 (ko) 2017-09-27

Similar Documents

Publication Publication Date Title
JP5442906B2 (ja) キナーゼインヒビターおよびこれを用いた癌の治療方法
JP5629752B2 (ja) キナーゼインヒビターおよびこれを用いた癌の治療方法
CN103080093A (zh) 吲唑化合物及其应用
CN105358544A (zh) 杂环化合物
KR20240120745A (ko) Rxfp1 수용체 효능제로서의 벤조티아졸, 벤조이속사졸 및 벤조디옥솔 유사체
RS55471B1 (sr) Inhibitori kinaze i njihova upotreba za lečenje kancera
HK1180315B (en) Kinase inhibitors and their use in treating cancer

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20130607

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130607

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20130607

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20130702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20130708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131002

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131218

R150 Certificate of patent or registration of utility model

Ref document number: 5442906

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250